Life sciences
Evidence from the point of care
Data generated during care, not reassembled from claims afterwards. Registries that collect themselves. Programmes that run inside the pathway. Slovakia and Czechia today.
- Generated inside the workflow
- FHIR R4 to OMOP CDM
- Every contributor is paid
9,410 patients
across five indications
24 to 72 hours
from recorded event to analysis
9,410
Patients across the five launch indications
96%
Completeness on core variables, multiple sclerosis
24 h
Fastest event to availability latency
2
Markets recording today, Slovakia and Czechia
Two pillars, two budgets
Bought by different people inside the same company.
Real-world data and registries
Generated during care, structured as FHIR R4 at entry, mapped to OMOP CDM. For medical affairs, market access and HTA.
Care Plans for patient services
The pathway made operational. A sponsor co-funds it for an indication. It is the same product the clinic and the patient use.
Consent, anonymisation, a share
Nothing leaves without a decision per programme. What leaves is anonymised, and patient, clinician and provider each take a share.
Central Europe first
Slovakia and Czechia today, on a platform where a new market is configuration. Almost no published evidence of this kind exists for the region.
What exists today
Cohorts, completeness and latency by indication, in the markets measured today.
| Indication | Markets | Cohort | Completeness on core variables | Latency |
|---|---|---|---|---|
| Multiple sclerosis | Slovakia, Czechia | 3,900 patients | 96% | 24 hours |
| Dementia | Slovakia | 1,450 patients | 89% | 48 hours |
| Colorectal | Slovakia, Czechia | 1,120 patients | 91% | 48 hours |
| Cardiac ablation | Slovakia | 640 patients | 94% | 24 hours |
| Obesity | Slovakia | 2,300 patients | 82% | 72 hours |
Monthly briefing
The signal, once a month.
What changed in European health data, what we shipped, and what it means for a provider. Nothing else.